Q-omics provides the consensus-scored GHITM profile across patient tissues and cancer cell-line models. GHITM expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GHITM is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GHITM protein abundance shows 20,602 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where GHITM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GHITM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GHITM survival associations across molecular data types. GHITM RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GHITM RNA expression–survival associations across cancer types. High GHITM expression shows unfavorable associations in HNSC, UVM and LUAD, but favorable associations in KIRC, LGG and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GHITM RNA expression.
This table summarizes GHITM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GHITM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GHITM shows lower tumor expression in KIRC, THCA, COAD, KIRP, READ and KICH. The KIRC box plot shows higher GHITM RNA expression in normal versus tumor tissue (log2 FC = −0.792, t-test p < 0.001).
This table shows molecular features associated with GHITM in patient tissues and cancer cell lines. In patient samples, GHITM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GHITM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
